Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 5:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 296 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: RE-ACTIVE Clear all
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT03536884
View directory record Official record
Conditions
Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis
Interventions
Bimekizumab, Secukinumab, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
743 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
25
States / cities
Santa Ana, California • Danbury, Connecticut • Ocala, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 19, 2026, 5:25 AM EDT
Recruiting Phase 2 Interventional

A Study on How to Safely Guide Surgery for Melanoma and Similar Skin Tumors in Children Using Pathology and Genetic Information

NCT07621614
View directory record Official record
Conditions
Clinical Stage 0 Cutaneous Melanoma AJCC v8, Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage II Cutaneous Melanoma AJCC v8, Cutaneous Melanocytic Neoplasm, Cutaneous Melanoma, Cutaneous Spitz Melanocytoma, Cutaneous Spitz Melanoma
Interventions
Biospecimen Collection, Chest Radiography, Computed Tomography, Fludeoxyglucose F-18, Magnetic Resonance Imaging, Patient Observation, Positron Emission Tomography, Re-Excision, Sentinel Lymph Node Biopsy, Ultrasound Imaging, Wide Local Excision
Procedure · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 25 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
13
States / cities
Oakland, California • Wilmington, Delaware • Jacksonville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 19, 2026, 5:25 AM EDT
Recruiting Phase 2 Interventional

Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors

NCT05194397
View directory record Official record
Conditions
Lymphoblastic Leukemia, Cancer Survivors, Aplastic Anemia, Myelodysplastic Syndromes, Myeloid Leukemia
Interventions
Nicotinamide Riboside, Placebo, Exercise Intervention
Dietary Supplement · Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
10 Years to 30 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Duarte, California • Philadelphia, Pennsylvania • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Oct 19, 2026, 5:25 AM EDT
Terminated Not applicable Interventional Results available

Celliant Socks to Increase Tissue Oxygenation and Complete Wound Closure in Diabetic Foot Wounds

NCT04709419
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
Celliant Diabetic Medical Socks, Control (placebo) Medical Socks
Device
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
22 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Oct 19, 2026, 5:25 AM EDT
Not yet recruiting Phase 2 Interventional

Nicotinamide for Retinal Protection in Primary Open-Angle Glaucoma (NADIR Trial)

NCT07808333
View directory record Official record
Conditions
Glaucoma, Open-angle, Primary Open Angle Glaucoma (POAG)
Interventions
Nicotinamide, Standard Glaucoma Therapy
Drug · Other
Lead sponsor
University of Chicago
Other
Eligibility
40 Years to 80 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 19, 2026, 5:25 AM EDT
Recruiting Not applicable Interventional

Personalized Health Self-Management Training for Colorectal Cancer Survivors

NCT05984589
View directory record Official record
Conditions
Colorectal Cancer, Healthy Lifestyle, Behavior, Health, Health Behavior, Gastrointestinal Cancers
Interventions
RISE Personalized Self-Management Training (PSMT), Standardized Self-Management Training (SSMT)
Behavioral
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 19, 2026, 5:25 AM EDT
Recruiting Phase 2 Interventional

DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment

NCT06075953
View directory record Official record
Conditions
Ductal Carcinoma in Situ
Interventions
Tamoxifen, Exemestane, Letrozole, Anastrazole, Testosterone + Anastrazole, Elacestrant, Z-endoxifen
Drug
Lead sponsor
QuantumLeap Healthcare Collaborative
Other
Eligibility
18 Years and older · Female only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2033
U.S. locations
29
States / cities
Berkeley, California • Duarte, California • Irvine, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 19, 2026, 5:25 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Re-energize With Nutrition, Exercise and Weight Loss

NCT00712127
View directory record Official record
Conditions
Obesity
Interventions
Diet and Exercise, Diet and Exercise-Delayed
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
30 Years to 55 Years
Enrollment
310 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Oct 19, 2026, 5:25 AM EDT
Not listed Phase 2 Interventional

Project RAP: Reaching Adolescents for Prevention

NCT00183157
View directory record Official record
Conditions
Alcohol Related Morbidity, Alcohol Dependence
Interventions
Brief Motivational Intervention, Assessment and list of resources, Referral to Community Resources
Behavioral
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
14 Years to 21 Years
Enrollment
1,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 13, 2009 · Synced Oct 19, 2026, 5:25 AM EDT
Completed Phase 3 Interventional Results available

A Study To Evaluate The Effects And Safety Of Treatment, Treatment Withdrawal, Followed By Re-Treatment With CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis

NCT01186744
View directory record Official record
Conditions
Psoriasis
Interventions
CP-690,550
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
666 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
50
States / cities
Mobile, Alabama • Tucson, Arizona • Fremont, California + 33 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2018 · Synced Oct 19, 2026, 5:25 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Sirolimus Injections for Autoimmune Scleritis

NCT01517074
View directory record Official record
Conditions
Scleritis
Interventions
Sirolimus
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 19, 2020 · Synced Oct 19, 2026, 5:25 AM EDT
Completed Not applicable Interventional Results available

Improving Physical Activity and Gait Symmetry After Total Knee Arthroplasty

NCT04090125
View directory record Official record
Conditions
Knee Replacement, Total, Knee Arthroplasty, Total
Interventions
PAS Intervention, Attention Control
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 5, 2024 · Synced Oct 19, 2026, 5:25 AM EDT
Completed Phase 3 Interventional Results available

Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TM

NCT03429543
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Metformin, Insulin, Placebo, Linagliptin, Empagliflozin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
10 Years to 17 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
44
States / cities
Phoenix, Arizona • Tucson, Arizona • Orange, California + 39 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2024 · Synced Oct 19, 2026, 5:25 AM EDT
Recruiting Not applicable Interventional

Promoting Improved Functioning Among People Experiencing Stressful Situations

NCT06482567
View directory record Official record
Conditions
Acute Stress Reaction
Interventions
iCOVER, Physical Presence with Reassurance
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 50 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
5
States / cities
Belmont, Massachusetts • Worcester, Massachusetts • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Oct 19, 2026, 5:25 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess Whether Etrolizumab is a Safe and Efficacious Treatment for Participants With Moderately to Severely Active Crohn's Disease

NCT02394028
View directory record Official record
Conditions
Crohn Disease
Interventions
Etrolizumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,035 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
62
States / cities
Arcadia, California • La Jolla, California • Long Beach, California + 53 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2022 · Synced Oct 19, 2026, 5:25 AM EDT
Completed Not applicable Interventional

'Food, Fun, Fresh, Family' Program for Healthy Eating and Growth for Elementary-age Children.

NCT06010784
View directory record Official record
Conditions
Diet, Healthy Growth
Interventions
Family support, BGCAA's after-school program with CATCH curriculum
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
5 Years to 11 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 19, 2026, 5:25 AM EDT
Completed Not applicable Interventional Results available

Respiratory Exacerbation Plans for Action and Care Transitions for Children With Severe CP

NCT05292365
View directory record Official record
Conditions
Cerebral Palsy
Interventions
RE-PACT Intervention
Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Los Angeles, California • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 19, 2024 · Synced Oct 19, 2026, 5:25 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Video Games for Obesity and Diabetes Prevention-Diab & Nano

NCT01846377
View directory record Official record
Conditions
Obesity, Type 2 Diabetes
Interventions
G4H-Diab-Nano
Behavioral
Lead sponsor
Baylor College of Medicine
Other
Eligibility
10 Years to 12 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 20, 2018 · Synced Oct 19, 2026, 5:25 AM EDT
Recruiting Not applicable Interventional

The ROAMM-EHR Study

NCT06263322
View directory record Official record
Conditions
Peripheral Arterial Disease, Chronic Limb-Threatening Ischemia
Interventions
Actionable remotely generated health data, Non-Actionable remotely generated health data
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
60 Years to 100 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 27, 2025 · Synced Oct 19, 2026, 5:25 AM EDT
Completed Phase 3 Interventional Results available

A Study of Flurbiprofen 8.75 mg Lozenge in Patients With Pharyngitis

NCT01048866
View directory record Official record
Conditions
Pharyngitis
Interventions
placebo, flurbiprofen, acetaminophen 650mg
Drug
Lead sponsor
Reckitt Benckiser LLC
Industry
Eligibility
18 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 21, 2017 · Synced Oct 19, 2026, 5:25 AM EDT
Not listed Not applicable Interventional

BFR DISTRAD: Blood Flow Restricted Training During Rehabilitation Following Distal Radius Fracture Repair

NCT02482727
View directory record Official record
Conditions
Distal Radius Fracture, Rehabilitation
Interventions
occlusion training with tourniquet (DELFI PTS ii portable tourniquet system)
Device
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2015
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 19, 2026, 5:25 AM EDT
Completed Phase 2Phase 3 Interventional

Prolonged Exposure Therapy for Post Traumatic Stress Disorder Following Sexual Assault

NCT00057629
View directory record Official record
Conditions
Stress Disorders, Post-Traumatic
Interventions
Prolonged Exposure (PE), Treatment as usual group therapy (TUGT), Supportive counseling (SC)
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 67 Years · Female only
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 13, 2015 · Synced Oct 19, 2026, 5:25 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Four Doses of Cenerimod Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus

NCT03742037
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Cenerimod 0.5 mg, Cenerimod 1 mg, Cenerimod 2 mg, Cenerimod 4 mg, Placebo, cenerimod 2 mg (ex-4 mg)
Drug
Lead sponsor
Viatris Innovation GmbH
Industry
Eligibility
18 Years to 75 Years
Enrollment
427 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
29
States / cities
Anniston, Alabama • La Jolla, California • Los Alamitos, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 19, 2026, 5:25 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in Patients With Branch Retinal Vein Occlusion (BRVO)

NCT01521559
View directory record Official record
Conditions
Branch Retinal Vein Occlusion
Interventions
Macular Laser Photocoagulation, Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)
Procedure · Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
45
States / cities
Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 42 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2014 · Synced Oct 19, 2026, 5:25 AM EDT